ProCE Banner Activity

Adult HBV Vaccination: Identifying Individuals at Risk for Reduced Seroprotection

Slideset Download
Downloadable slideset highlighting best practices in identifying adults who may be at risk for reduced HBV seroprotection and in applying current HBV vaccine recommendations in special populations.

Released: April 13, 2022

Expiration: April 12, 2023

No longer available for credit.

Share

Faculty

Robert G. Gish

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

VBI Vaccines Inc

Faculty Disclosure

Primary Author

Robert G. Gish, MD

Medical Director
Complex GI and Specialty Services
California Pacific Medical Center
San Francisco, California

Robert G. Gish, MD, has disclosed that he has received funds for research support from has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Fibronostics, Fujifilm/Wako, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, Hepatx, HepQuant, Intercept, Janssen, Merck, Perspectum, Pfizer, Quest, Sonic Incytes, and Topography Health, and Venatorx; has served on advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer and Prodigy; serves on current clinical trials alliance for Topography Health; and has served on data and safety monitoring boards for Altimmune, Arrowhead, CymaBay, and Durect; serves on speakers bureaus for AbbVie, BMS, Eisai, Genentech, Gilead Sciences, and Intercept; and has stock options with Eiger, Genlantis, HepQuant, AngioCrine, HepaTx.